<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002878</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065178</org_study_id>
    <secondary_id>E-1A95</secondary_id>
    <secondary_id>CAN-NCIC-MY8</secondary_id>
    <secondary_id>CLB-E1A95</secondary_id>
    <secondary_id>EORTC-E1A95/06971</secondary_id>
    <secondary_id>SWOG-E1A95</secondary_id>
    <secondary_id>CAN-NCIC-J1A95</secondary_id>
    <secondary_id>CLB-9596</secondary_id>
    <secondary_id>SWOG-S1A95</secondary_id>
    <nct_id>NCT00002878</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining PSC&#xD;
      833 with chemotherapy may reduce resistance to the drug, and allow more tumor cells to be&#xD;
      killed. It is not yet known whether combination chemotherapy plus PSC 833 is more effective&#xD;
      than combination chemotherapy alone in treating patients with relapsed or refractory multiple&#xD;
      myeloma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy&#xD;
      with or without PSC 833 in treating patients with relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall survival and objective response rate of patients with relapsed or&#xD;
           refractory multiple myeloma treated with vincristine, doxorubicin, and dexamethasone&#xD;
           (VAD) with or without PSC 833.&#xD;
&#xD;
        -  Compare event free survival and subjective response in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Correlate treatment outcome with p-glycoprotein expression.&#xD;
&#xD;
        -  Determine whether prognostic factors previously determined to be useful in untreated&#xD;
           patients (i.e., plasma cell labeling index and multidrug resistance determined from bone&#xD;
           marrow aspirates, serum beta 2-microglobulin and interleukin-6 receptor levels)&#xD;
           correlate with objective and subjective response and event-free and overall survival in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of VAD with or without PSC 833.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified by response to&#xD;
      prior treatment, prior doxorubicin and/or vincristine, prior autologous peripheral blood stem&#xD;
      cell transplantation, and center.&#xD;
&#xD;
      Patients are randomized to 1 of 2 treatment arms:&#xD;
&#xD;
        -  Arm I: The first group receives vincristine, doxorubicin, and dexamethasone (VAD).&#xD;
           Patients receive higher dose vincristine IV over 96 hours and higher dose doxorubicin IV&#xD;
           over 96 hours on days 1-4 and oral dexamethasone daily on days 1-4 and 15-18.&#xD;
&#xD;
        -  Arm II: The second group receives VAD plus oral PSC 833. Patients receive oral PSC 833&#xD;
           every 6 hours beginning on day 1 and continuing for 20 doses. Patients receive lower&#xD;
           dose vincristine IV over 96 hours and lower dose doxorubicin IV over 96 hours on days&#xD;
           2-5 and oral dexamethasone daily on days 2-5 and 16-19.&#xD;
&#xD;
      Treatment in both arms repeats every 4 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity. After completion of 2 courses, patients are reevaluated, and those&#xD;
      with stable or responding disease continue treatment for 2 courses beyond maximum response.&#xD;
      Doxorubicin is discontinued in patients who receive a maximum lifetime dose but still have&#xD;
      stable or responding disease.&#xD;
&#xD;
      Patients are followed every 2 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study over approximately&#xD;
      20 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1997</start_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valspodar</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Multiple myeloma of any stage confirmed by:&#xD;
&#xD;
               -  Bone marrow plasmacytosis with at least 10% plasma cells, sheets of plasma cells,&#xD;
                  or biopsy proven plasmacytosis&#xD;
&#xD;
               -  Myeloma (M) protein in serum and/or urine&#xD;
&#xD;
          -  Measurable disease by at least one of the following:&#xD;
&#xD;
               -  Serum M-component at least 1.0 g/dL by electrophoresis&#xD;
&#xD;
                    -  Baseline measurement by nephelometry also, if used to follow response&#xD;
&#xD;
               -  Urine M-protein excretion greater than 200 mg/24 hours by electrophoresis&#xD;
&#xD;
          -  The following are not considered measurable but are followed for response:&#xD;
&#xD;
               -  Lytic bone lesions&#xD;
&#xD;
               -  Bone marrow plasmacytosis&#xD;
&#xD;
               -  Anemia&#xD;
&#xD;
               -  Serum beta 2-microglobulin&#xD;
&#xD;
          -  Objective evidence of progression by at least one of the following:&#xD;
&#xD;
               -  Increased serum M-protein (by electrophoresis unless M-spike less than 1.5 g/dL)&#xD;
&#xD;
                    -  At least 50% above lowest remission level or by at least 2 g/dL&#xD;
&#xD;
                    -  To more than 1.0 g/dL if sole protein indication of relapse&#xD;
&#xD;
                    -  Nephelometry may be used instead of electrophoresis&#xD;
&#xD;
               -  Increased urine M-protein&#xD;
&#xD;
                    -  To 50% above lowest level OR by 2 g/24 hours&#xD;
&#xD;
                    -  To greater than 200 mg/24 hours&#xD;
&#xD;
               -  Definite new lytic bone lesions or at least a 50% increase in size of existing&#xD;
                  lesions (discussion with ECOG Study Chairman required if sole indication of&#xD;
                  progression)&#xD;
&#xD;
               -  Increase in serum or urine M-protein by 25% to under 50% (as above) plus one of&#xD;
                  the following:&#xD;
&#xD;
                    -  Serum calcium greater than 12 mg/dL without other cause&#xD;
&#xD;
                    -  Hemoglobin decreased by more than 2.0 g/dL not attributed to chemotherapy,&#xD;
                       interferon therapy, or a myelodysplastic syndrome&#xD;
&#xD;
                         -  Less than 11 g/dL in men&#xD;
&#xD;
                         -  Less than 10 g/dL in women&#xD;
&#xD;
                    -  At least a 50% increase in bone marrow plasmacytosis&#xD;
&#xD;
          -  Failure of prior cytotoxic therapy defined by one of the following:&#xD;
&#xD;
               -  Never responded&#xD;
&#xD;
               -  Relapsed within 2 months of last treatment&#xD;
&#xD;
               -  Relapsed 2-12 months after last treatment following initial response&#xD;
&#xD;
          -  Adequate prior chemotherapy required, e.g.:&#xD;
&#xD;
               -  At least 2 courses of combination chemotherapy (e.g., VBMCP, VBAP, MP)&#xD;
&#xD;
                    -  Prior vincristine, doxorubicin, and dexamethasone (VAD) allowed&#xD;
&#xD;
                         -  No demonstrated resistance to VAD&#xD;
&#xD;
                         -  At least 3 months since prior VAD&#xD;
&#xD;
                    -  Cumulative doxorubicin dose no more than 250 mg/m2&#xD;
&#xD;
                    -  Prior autologous peripheral blood stem cell transplant allowed if performed&#xD;
                       prior to development of drug resistance&#xD;
&#xD;
                         -  No prior allogeneic transplant&#xD;
&#xD;
          -  No smoldering myeloma, localized plasmacytoma, or monoclonal gammopathy of&#xD;
             undetermined significance (MGUS)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST less than 1.5 times ULN&#xD;
&#xD;
          -  No chronic or active hepatitis or cirrhosis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 3.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 50%&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  No overt angina despite medication&#xD;
&#xD;
          -  No myocardial infarction within 2 months&#xD;
&#xD;
          -  No poorly controlled hypertension (i.e., pressure 200/110 or higher despite&#xD;
             medication)&#xD;
&#xD;
          -  No arrhythmia requiring therapy (i.e., sustained atrial or ventricular arrhythmia or&#xD;
             multifocal premature ventricular contraction)&#xD;
&#xD;
               -  Digoxin to control ventricular rate of atrial fibrillation that has been chronic&#xD;
                  for more than 1 month allowed&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No peripheral neuropathy with weakness&#xD;
&#xD;
          -  No cerebellar disease with ataxia&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  Adequate gastrointestinal function to allow absorption of PSC 833&#xD;
&#xD;
          -  No active peptic ulcer&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No hypersensitivity to PSC 833 or cyclosporine&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No second malignancy within the past 5 years except curatively treated nonmelanomatous&#xD;
             skin cancer, carcinoma in situ of the cervix, or other localized cancer treated with&#xD;
             surgery alone&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other serious medical problem unless sufficiently stabilized&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior biologic therapy (e.g., interferon) allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since other prior chemotherapy (including plicamycin)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 2 weeks since high dose steroids (at least 100 mg/m2/day of prednisone or at&#xD;
             least 40 mg/day of dexamethasone (including steroids for hypercalcemia)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy except limited radiotherapy to a single bone&#xD;
             lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
          -  No concurrent drugs known to modulate cyclosporine blood concentrations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William R. Friedenberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guthrie Cancer Center at Guthrie Clinic Sayre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl H. Hanson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Saint Luke's Cancer Institute at Saint Luke's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard A. Larson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaim Shustik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Victoria Hospital - Montreal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pieter Sonneveld, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Rotterdam at Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marlene &amp; Stewart Greenebaum Cancer Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southern Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Hospital at North Shore</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Cornell Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southeast Cancer Control Consortium</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104-4241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee, Memphis Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401-3498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6ZB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Health Sciences Hospital - Niagara</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 5K3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario - Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L-4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006 Feb 15;106(4):830-8. doi: 10.1002/cncr.21666.</citation>
    <PMID>16419071</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>August 28, 2013</last_update_submitted>
  <last_update_submitted_qc>August 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2013</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

